Kiniksa Pharmaceuticals Ltd (KNSA) Fair Value & Analysis
Healthcare · US · Market cap $4.9B · ISIN BMG5269C1010
What is Kiniksa Pharmaceuticals Ltd really worth?
Kiniksa Pharmaceuticals Ltd
KNSA · US
A solid business, but trading 248% above our fair value of $23.15.
Strengths
Risks
Fair value as of: Aug 28, 2026
From 24 valuation models · updated 8 days ago
Share price +5.9% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($28.22). The favourable scenario is already priced in.
- Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
60‑month range $7.60 – $80.92 · fair‑value band $15.89 – $28.22 · the $80.47 price screens above the $23.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 28, 2026.
Analysis
Kiniksa Pharmaceuticals Ltd (KNSA) currently trades at $80.47, while our model-based Fair Value estimate is $23.15, implying the stock looks roughly 247.7% overvalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of $59.20 per share, and 0 of the 24 models we run sit above the $80.47 price. Bear case: the Asset-Based group reads lowest at $8.21, and 24 of the 24 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Kiniksa Pharmaceuticals Ltd generated revenue of $754M at a net margin of 9.7%. Revenue grew 55.5% year over year. It earns a return on equity of 13.7%. The balance sheet holds a net cash position of $156M. Fundamentals as of Aug 28, 2026
Our scenario range runs from $15.89 (bear case) to $28.22 (bull case); at $80.47, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 206% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −71%, KNSA screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $0.6158 per share, which is 2.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: Growth Earnings ($59.20) versus Asset-Based ($8.21). Highest evidence: FCF DCF (73).
Notify me when KNSA reaches fair value
Put KNSA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 89
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Full company description
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kiniksa Pharmaceuticals Ltd reported revenue of $678M in FY2025 versus $38.5M in FY2021, a compound +104.8%/yr. Reported net income was $59.0M in FY2025.
KNSA screens 248% overvalued. Compare with Merck KGaA →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan
- Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
- KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Kiniksa Pharmaceuticals Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Kiniksa Pharmaceuticals Ltd (KNSA) overvalued or undervalued?
What is the fair value of KNSA?
What is the quality score of KNSA?
What is the revenue of Kiniksa Pharmaceuticals Ltd (KNSA)?
What is the net profit margin of KNSA?
Watch Kiniksa Pharmaceuticals Ltd in the live analysis
One click puts Kiniksa Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.